Cargando…
Variability in grading of ductal carcinoma in situ among an international group of pathologists
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. H...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073001/ https://www.ncbi.nlm.nih.gov/pubmed/33620141 http://dx.doi.org/10.1002/cjp2.201 |
_version_ | 1783684032967475200 |
---|---|
author | van Seijen, Maartje Jóźwiak, Katarzyna Pinder, Sarah E Hall, Allison Krishnamurthy, Savitri Thomas, Jeremy SJ Collins, Laura C Bijron, Jonathan Bart, Joost Cohen, Danielle Ng, Wen Bouybayoune, Ihssane Stobart, Hilary Hudecek, Jan Schaapveld, Michael Thompson, Alastair Lips, Esther H Wesseling, Jelle |
author_facet | van Seijen, Maartje Jóźwiak, Katarzyna Pinder, Sarah E Hall, Allison Krishnamurthy, Savitri Thomas, Jeremy SJ Collins, Laura C Bijron, Jonathan Bart, Joost Cohen, Danielle Ng, Wen Bouybayoune, Ihssane Stobart, Hilary Hudecek, Jan Schaapveld, Michael Thompson, Alastair Lips, Esther H Wesseling, Jelle |
author_sort | van Seijen, Maartje |
collection | PubMed |
description | The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. Haematoxylin and eosin‐stained slides of 425 women with primary DCIS were independently reviewed by nine breast pathologists based in the Netherlands, the UK, and the USA. Chance‐corrected kappa (κ (ma)) for association between pathologists was calculated based on a generalised linear mixed model using the ordinal package in R. Overall κ (ma) for grade of DCIS (low, intermediate, or high) was estimated to be 0.50 (95% confidence interval [CI] 0.44–0.56), indicating a moderate association between pathologists. When the model was adjusted for national guidelines, the association for grade did not change (κ (ma) = 0.53; 95% CI 0.48–0.57); subgroup analysis for pathologists using the UK pathology guidelines only had significantly higher association (κ (ma) = 0.58; 95% CI 0.56–0.61). To assess if concordance of grading relates to the expression of the oestrogen receptor (ER) and HER2, archived immunohistochemistry was analysed on a subgroup (n = 106). This showed that non‐high grade according to the majority opinion was associated with ER positivity and HER2 negativity (100 and 89% of non‐high grade cases, respectively). In conclusion, DCIS grade showed only moderate association using whole slide images scored by nine breast pathologists. As therapeutic decisions and inclusion in ongoing clinical trials are guided by DCIS grade, there is a pressing need to reduce interobserver variability in grading. ER and HER2 might be supportive to prevent the accidental and unwanted inclusion of high‐grade DCIS in such trials. |
format | Online Article Text |
id | pubmed-8073001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80730012021-04-29 Variability in grading of ductal carcinoma in situ among an international group of pathologists van Seijen, Maartje Jóźwiak, Katarzyna Pinder, Sarah E Hall, Allison Krishnamurthy, Savitri Thomas, Jeremy SJ Collins, Laura C Bijron, Jonathan Bart, Joost Cohen, Danielle Ng, Wen Bouybayoune, Ihssane Stobart, Hilary Hudecek, Jan Schaapveld, Michael Thompson, Alastair Lips, Esther H Wesseling, Jelle J Pathol Clin Res Original Articles The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. Haematoxylin and eosin‐stained slides of 425 women with primary DCIS were independently reviewed by nine breast pathologists based in the Netherlands, the UK, and the USA. Chance‐corrected kappa (κ (ma)) for association between pathologists was calculated based on a generalised linear mixed model using the ordinal package in R. Overall κ (ma) for grade of DCIS (low, intermediate, or high) was estimated to be 0.50 (95% confidence interval [CI] 0.44–0.56), indicating a moderate association between pathologists. When the model was adjusted for national guidelines, the association for grade did not change (κ (ma) = 0.53; 95% CI 0.48–0.57); subgroup analysis for pathologists using the UK pathology guidelines only had significantly higher association (κ (ma) = 0.58; 95% CI 0.56–0.61). To assess if concordance of grading relates to the expression of the oestrogen receptor (ER) and HER2, archived immunohistochemistry was analysed on a subgroup (n = 106). This showed that non‐high grade according to the majority opinion was associated with ER positivity and HER2 negativity (100 and 89% of non‐high grade cases, respectively). In conclusion, DCIS grade showed only moderate association using whole slide images scored by nine breast pathologists. As therapeutic decisions and inclusion in ongoing clinical trials are guided by DCIS grade, there is a pressing need to reduce interobserver variability in grading. ER and HER2 might be supportive to prevent the accidental and unwanted inclusion of high‐grade DCIS in such trials. John Wiley & Sons, Inc. 2021-02-23 /pmc/articles/PMC8073001/ /pubmed/33620141 http://dx.doi.org/10.1002/cjp2.201 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles van Seijen, Maartje Jóźwiak, Katarzyna Pinder, Sarah E Hall, Allison Krishnamurthy, Savitri Thomas, Jeremy SJ Collins, Laura C Bijron, Jonathan Bart, Joost Cohen, Danielle Ng, Wen Bouybayoune, Ihssane Stobart, Hilary Hudecek, Jan Schaapveld, Michael Thompson, Alastair Lips, Esther H Wesseling, Jelle Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title | Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title_full | Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title_fullStr | Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title_full_unstemmed | Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title_short | Variability in grading of ductal carcinoma in situ among an international group of pathologists |
title_sort | variability in grading of ductal carcinoma in situ among an international group of pathologists |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073001/ https://www.ncbi.nlm.nih.gov/pubmed/33620141 http://dx.doi.org/10.1002/cjp2.201 |
work_keys_str_mv | AT vanseijenmaartje variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT jozwiakkatarzyna variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT pindersarahe variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT hallallison variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT krishnamurthysavitri variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT thomasjeremysj variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT collinslaurac variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT bijronjonathan variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT bartjoost variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT cohendanielle variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT ngwen variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT bouybayouneihssane variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT stobarthilary variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT hudecekjan variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT schaapveldmichael variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT thompsonalastair variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT lipsestherh variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT wesselingjelle variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists AT variabilityingradingofductalcarcinomainsituamonganinternationalgroupofpathologists |